Exploring Rosiglitazone’s Potential to Treat Alzheimer’s Disease through the Modulation of Brain-Derived Neurotrophic Factor
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that debilitates over 55 million individuals worldwide. Currently, treatments manage and alleviate its symptoms; however, there is still a need to find a therapy that prevents or halts disease progression. Since AD has been labeled...
Main Authors: | Mackayla L. Nelson, Julia A. Pfeifer, Jordan P. Hickey, Andrila E. Collins, Bettina E. Kalisch |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-7737/12/7/1042 |
Similar Items
-
Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients
by: Chin-Hsiao Tseng, et al.
Published: (2023-07-01) -
European Medicines Agency (EMA) announces termination of Avandia (rosiglitazone usage in Europe)
by: Inna Igorevna Klefortova
Published: (2010-09-01) -
Effect of Rosiglitazone on Coronary Angiogenesis in Diabetic and Control Rats
by: Ensieh Salehi, et al.
Published: (2011-06-01) -
Possible modulation of the antidiabetic effect of rosiglitazone by buspirone
by: Wafaa R. Mohamed, et al.
Published: (2012-06-01) -
Naturally Occurring Antioxidant Therapy in Alzheimer’s Disease
by: Andrila E. Collins, et al.
Published: (2022-01-01)